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Background: Prasugrel, a novel thienopyridine antiplatelet drug significantly reduces rates
of stent thrombosis compared to clopidogrel, the current standard therapy, clopidogrel.
However, it has been associated with an increased risk of both minor as well as major
bleeding, including fatal bleeding.
Objective: Theobjectiveof thisstudywastodocument therateofadverseeventsofprasugrel in
clinical practice in acute coronary syndrome (UA/NSTEMI & STEMI undergoing PCI).
Methods: This was a multicentre, open-labeled, prospective, naturalistic study. A total of
2592 patients of STEMI or NSTEMI for primary or delayed PCI on prasugrel 60 mg loading
and 10 mg of maintenance dose were enrolled. Outcome measures were stent thrombosis,
death and major/minor bleeding over a follow-up period of three months.
Results: Of the 2592 patients, 14 were terminated from therapy. Out of 2578 patients, 1099
(42.6%) were STEMI and 814 (31.6) UA/NSTEMI, 2022 (78.3%) were male and 560 (21.7%) fe-
male. 1180 (45.8%) were diabetics. The average age of patients was 55.65 years. At the end of
three months there was no death in study population. 43 (1.6%) patients experienced
adverse events. Bleeding and chest pain were the most common (n ¼ 9, 0.3% each), followed
by gastritis in 5 patients (0.2%), weakness in 4 (0.2%) and vomiting in 3 patients (0.1%).
Conclusion: Prasugrel was well-tolerated, with a good safety profile, and the most common
side effects being bleeding and chest pain.
Copyright ª 2013, Cardiological Society of India. All rights reserved.
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IHJ206_proof ■ 29 April 2013 ■ 2/5acute thrombotic events.2,3 These factors are especially
important in the initiation of the intracoronary thromboses
which can result in ACS and the ischemic complications of
coronary artery interventions, like recurrent myocardial
infarction (MI) and stent thrombosis.4
Considering the importance of platelets in the pathogenesis
of ACS, the role of antiplatelet agents in the management and
prevention of the complications after ACS and percutaneous
coronary intervention (PCI) cannot be overemphasized.3
Low-dose aspirin therapy has been the mainstay anti-
platelet therapy for many years. It acts by irreversibly acety-
lating cyclooxygenase 1 (COX-1) enzyme, and thus preventing
the conversion of arachidonic acid to thromboxane A2 in the
platelets. This results in reduction of overall platelet aggrega-
tion at the site of the vascular injury. However, platelet acti-
vation can occur by COX-1 independent pathways also like
collagen and adenosine diphosphate.5,6 This has led to the
development of drugs inhibiting these alternate pathways.
Antiplatelet drugs belonging to the thienopyridine group
which act by inhibiting the ADP-induced platelet aggregation
by blocking the P2Y12 receptors are a major advancement in
the management of ACS patients undergoing PCI. This group
includes 3 drugs: ticlopidine, clopidogrel, and prasugrel.
Although ticlopidine was shown to be beneficial,7,8 its use is
currently limited by the need to take the drug twice daily, poor
tolerability, especially gastrointestinal discomfort and serious
adverse effects like bone marrow aplasia.9 A dual antiplatelet
therapy of clopidogrel with aspirin is currently the standard of
care for this group of patients.10,11 Although proven to be
beneficial, there have been many reports of recurrent athero-
thrombotic events while receiving this dual antiplatelet ther-
apy.12 Additionally, clopidogrel is also associated with three
important limitations: amodest antiplatelet effect, substantial
interpatient variability and a delayed onset of action.2
Prasugrel is a novel thienopyridine antiplatelet agent,
approved for the treatment of patients with ACS undergoing
PCI in 2009.2 Prasugrel inhibits platelet aggregation more
rapidly, more consistently and to a greater extent compared
to clopidogrel.13e16 Several multicentre trials including
JUMBO-TIMI 26,17 PRINCIPLE-TIMI 44,16 and TRITON-TIMI 3818
demonstrated that prasugrel shows greater inhibition of
platelet aggregation and lower rates of the composite
endpoint of death, non-fatal myocardial infarction, and
stroke compared with clopidogrel. However, major bleeding
was more frequent with prasugrel than with clopidogrel.
Considering the availability and increasing usage of prasugrel
in India we conducted a study in 82 centers to evaluate effi-
cacy and safety of prasugrel in ACS patients undergoing PCI.249
250
251
252
253
254
255
256
257
258
259
2602. Patients and methods
This was a multicentre, open-labeled, prospective, natural-
istic study of the adverse event rate of prasugrel in routine
clinical practice, conducted from March 1, 2011 to July 15,
2011. Patients with STEMI or NSTEMI who underwent primary
or delayed PCI treated with prasugrel 60 mg loading dose and
10 mg per day maintenance dose were included in the study.
The patients were followed up for a period of three months to
document adverse events (if any).Please cite this article in press as: HiremathMS, et al., Prasugrel th
(IPUP) study in Indian patients, Indian Heart Journal (2013), http:In patients >75 years of age, prasugrel was generally not
recommended because of the increased risk of fatal and
intracranial bleeding and uncertain benefit; however, in high-
risk patients (e.g., those with diabetes or prior MI), where its
beneficial effects appear to be greater, it was prescribed.
Additionally, prasugrel was not advised to patients likely to
undergo urgent coronary artery bypass graft surgery (CABG).
Patients <60 kg body weight and those on any concomitant
medications that increase the risk of bleeding were also
excluded from the study.
The outcome measures were stent thrombosis, death and
major/minor bleeding over a follow-up period of 3 months.
The association of comorbid diabetes and adverse eventswere
specifically studied, considering that diabetes mellitus is a
major risk factor for the development of coronary artery
disease.
Since prasugrel was used in the setting of normal clinical
practice and this was not an experimental study but a natu-
ralistic surveillance, no specific approval was necessary. The
trial was performed in accordance with the principles of the
Declaration of Helsinki, ethical principles consistent with
good clinical practice and following locally applicable regula-
tory guidelines for post-marketing studies.3. Statistical analysis
Descriptive statistical analysis methods have been used. Re-
sults on continuous measurements are presented as mean (
standard deviation) and results on categorical measurements
are presented in number (%). The primary outcomes were
assessed based on the intention-to-treat (ITT) population,
who are defined as patients with at least one dose of study
medication and at least one post-baseline assessment for lipid
profile. Between groups comparison was assessed by using
Chi-square test for parameters on categorical scale. Level of
significance was considered as 0.05.4. Results
4.1. Baseline characteristics
A total of 2592 patients were included in the study fromMarch
1 to April 15, 2011. Of them, 14 were terminated from therapy,
and 2578 were followed up for a period of 3 months, that is
from June 1 to July 15, 2011, and included in the evaluation.
Table 1 shows the baseline parameters of these patients.
At baseline, 49.7%, 48.8% and 45.8% of the patients had a
history of hypercholesterolemia, hypertension and diabetes
mellitus respectively. Additionally, 42.6% had STEMI while
31.6% had UA/NSTEMI. About one-fourth of the patients had a
previous history of myocardial infarction. Additionally, vital
signs like systolic blood pressure, diastolic blood pressure and
pulse rate were within normal limits.
4.2. Percutaneous interventional procedures
Of the 2216 patients assessed, in majority of them (72.3%), one
stent had been placed, followed by two stents in about one-erapy in ACS PCI patients: In-practice usage and performance
//dx.doi.org/10.1016/j.ihj.2013.04.025
Table 1 e Baseline parameters.
Parameters Mean  standard deviation
Age (years; n ¼ 2513; mean  SD) 55.65  09.79
Weight (kg; n ¼ 2256; mean  SD) 70.61  09.43
Sex (%) (n ¼ 2582)
 Male 2022 (78.3)
 Female 560 (21.7)
History [n ¼ 2578; n (%)]
 Prior MI 0662 (25.7)
 Prior CABG 0098 (3.8)
 Post CABG 0002 (0.08)
 Prior CVA/TIA 0062 (2.4)
 Hypertension 1257 (48.8)
 Hyperthyroidism 0003 (0.1)
 Hypercholesterolemia 1282 (49.7)
 Diabetes 1180 (45.8)
 STEMI 1099 (42.6)
 UA/NSTEMI 0814 (31.6)
Vital signs (mean  SD)
 Systolic blood pressure (mmHg) 136.12  19.00
 Diastolic blood pressure (mmHg) 84.86  10.90
 Pulse rate (beats/minute) 81.65  11.84
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Fig. 2 e Type of stents used.
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IHJ206_proof ■ 29 April 2013 ■ 3/5fourth of the patients (see Fig. 1). Drug-eluting stents consti-
tuted 73.2% of the stents used of the 2177 patients assessed,
while bare metal stents comprised 25% (see Fig. 2).
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3684.3. Adverse events
There were totally 45 adverse events among 43 patients (1.6%,
Table 2). The most common events were minor bleeding and
chest pain in 9 patients (0.3%) each. This was followed by
gastritis (n ¼ 5, 0.2%), weakness (n ¼ 4, 0.2%) and vomiting
(n ¼ 3, 0.1%). Most of the events were mild-to-moderate.
Additionally, when the association of diabetes mellitus
with incidence of adverse events was studied, it was observed
that 19 patients each in the diabetes group (n¼ 1180, 1.6%) and
non-diabetes group (n ¼ 1398, 1.4%) had adverse events. The
difference was not statistically significant ( p > 0.05). The
incidence of adverse events was higher among those aged751601 
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Fig. 1 e Number of stents used.
Please cite this article in press as: HiremathMS, et al., Prasugrel th
(IPUP) study in Indian patients, Indian Heart Journal (2013), http:years (6 out of 48; 12.5%) compared to those <75 years of age
(34 out of 2464; 1.4%; p < 0.05).5. Discussion
The efficacy of prasugrel as an antiplatelet agent in patients
with ACS undergoing PCI has been studied in several trials.
Three such trials have led to its approval: JUMBO-TIMI 26,17
PRINCIPLE-TIMI 4416 and TRITON-TIMI 38.18 The key benefits
of prasugrel over clopidogrel are that it is more rapid, more
consistent and shows greater inhibition of platelet
aggregation.13e16 However, one major concern with the use of
prasugrel has been the associated increased risk in bleeding.
In the current study, to document the adverse events rate
of prasugrel in clinical practice, it was observed that bleeding
and chest pain were themost common adverse events seen inTable 2 e Incidence of adverse events.
Events No. of cases (n ¼ 2592) Percentage
Minor bleeding 09 00.3
Angina 01 0.04
Chest pain 09 00.3
Eczema 01 0.04
Epistaxis 01 0.04
Gastritis 05 00.2
Hemoptysis 02 0.08
Hemetemesis 02 0.08
Hematoma at punction 01 0.04
Melena 01 0.04
Weakness 04 00.2
Petechiae 02 0.08
Stent thrombosis 01 0.04
Abdomen pain 01 0.04
Pain 01 0.04
Vomiting 03 00.1
Others 01 0.04
No. of patients 43 01.6
No. of events 45 01.7
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IHJ206_proof ■ 29 April 2013 ■ 4/59 patients (0.3%) each. In the Joint Utilization of Medications to
Block Platelets Optimally (JUMBO-TIMI 26) study,17 there was
no significant difference in non-CABG bleeding between those
receiving prasugrel and clopidogrel at 30 days (1.7% vs. 1.2%
respectively) or in TIMI major and minor bleeding. However,
there were more TIMI minor bleeding events in the prasugrel
high-dose regimen group (60 mg loading dose and 15 mg
maintenance dose, 3.6%) compared to the intermediate-
(60 mg loading dose and 10 mg maintenance dose, 1.5%) or
low-dose regimen (45 mg loading dose and 7.5 mg mainte-
nance dose, 2.0%) groups and to the clopidogrel group (300 mg
loading dose and 75 mgmaintenance dose, 2.4%). However, in
The Prasugrel in Comparison to Clopidogrel for Inhibition of
Platelet Activation and Aggregation (PRINCIPLE-TIMI 44)
study16 in which 201 patients were randomized to receive
either prasugrel or clopidogrel, only 2 patients in the prasugrel
group had TIMI minor bleeding compared to none in the clo-
pidogrel group. In the TRITON-TIMI 38 study,18 there was an
excess of non-CABG-related major bleeding ( p ¼ 0.03), non-
CABG-related TIMI major or minor bleeding ( p ¼ 0.002) and
bleeding requiring transfusion ( p < 0.001). Additionally, there
was an increase in spontaneous bleeding with prasugrel vs.
clopidogrel, but the rates were lower and similar for instru-
mented bleeding, bleeding related to trauma and intracranial
bleeding. By 30 days of treatment, there was no significant
difference between the two groups, but after that a significant
excess in TIMI major bleeding ( p ¼ 0.34) was observed in the
prasugrel group compared to clopidogrel group ( p ¼ 0.03),
which was most commonly spontaneous bleeding.
However, the recently published results of the TRILOGY-
ACS study showed that among patients with UA/NSTEMI,
the risks of bleeding was similar between prasugrel and clo-
pidogrel when evaluated longterm, that is up to 30 months.19
Additionally, this study showed that there was no significant
between-group difference in the frequency of other serious
adverse events, except for a higher frequency of heart failure
in the clopidogrel group. In an Indian study on 220 patients
undergoing PCI, there were no major bleeding events with
either prasugrel or clopidogrel, but five patients in prasugrel
and one patient in clopidogrel group had minor episodes of
bleeding.20
In our study, there was no difference in the incidence of
adverse events between patients who had and did not have
diabetes mellitus ( p > 0.05). This finding was in line with that
of the TRITON-TIMI 38, where there was no excess in TIMI
major bleeding in patients with diabetes vs. those who did
not.18
The incidence of adverse events was higher in patients75
years of age compared to those <75 years (12.5% vs. 1.4%). In
the TRITON-TIMI 38,18 there were higher absolute TIMI major
bleeding rates in patients 75 years vs. those who were
younger (4.2% versus 3.4%; HR, 1.36; p ¼ 0.24). Additionally,
there was a higher rate of spontaneous fatal hemorrhage in
the older patients (prasugrel group, 9 vs. clopidogrel group, 0)
compared to younger patients (prasugrel group, 5 vs. clopi-
dogrel group, 4).
One more concern with the use of prasugrel has been in
patients with a body weight less than 60 kg, in whom the
exposure to the active metabolite of prasugrel is increased,
which can result in higher risk of bleeding.18 However, in ourPlease cite this article in press as: HiremathMS, et al., Prasugrel th
(IPUP) study in Indian patients, Indian Heart Journal (2013), http:study all patients weighed over 60 kg, and this was not a
concern.
Based on the findings of the current study, we conclude
that prasugrel may be an effective agent in the manage-
ment of ACS patients undergoing PCI, although it is asso-
ciated with a minor but definite increase in the risk of
bleeding. Additionally, it may be beneficial in patients with
diabetes, considering that diabetes is an important risk
factor for coronary artery disease and ACS. However, pra-
sugrel has to be cautiously used in patients older than 75
years and weighing <60 kg because of the associated
increased bleeding risk.Conflicts of interest
All authors have none to declare.
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